Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.44 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898575 | 1.00 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL30186355 | 0.86 | ESR1 (0.62) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL29607244 | 0.81 | L3MBTL1 (0.60) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL7600132 | 0.81 | L3MBTL1 (0.60) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL3230513 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL9919058 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL9922439 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL9919060 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL422211 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 | |
| SCHEMBL31723363 | 0.79 | L3MBTL1 (0.59) | L3MBTL1KDM4EIP6K1ACVR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192454-B1 | AZABICYCLO-AMINO-TRIAZINE COMPOUNDS FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES | SKYHAWK THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4634171-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4351582-B1 | COMBINATION OF A PARTICULAR BRAF INHIBITOR (PARADOX BREAKER) AND A PD-1 AXIS BINDING ANTAGONIST FOR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-20250215008-A1 | PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR | Haisco Pharmaceutical Group Co., Ltd. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4559913-A1 | PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR | Haisco Pharmaceutical Group Co., Ltd. (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-119585269-A | Preparation and use of quinazolinone derivatives as kinase inhibitors | 海思科医药集团股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4073065-B1 | NEW METHYLQUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841289-B2 | Heterocyclic derivatives | MERCK SHARP & DOHME B.V. (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2012118492-A1 | HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | ORGANON BIOSCIENCES NEDERLAND B.V. (NL) | 2012-08-16 | — | — | US | disclosed |
| WO-2011045258-A1 | CONDENSED AZINE - DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE ACETYLCHOLINE RECEPTOR | N.V. ORGANON (NL) | 2011-04-21 | — | — | WO | disclosed |
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-2010504-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007119055-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215008-A1 | PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR | BRAF, RAF1, NRAS | L3MBTL1 4751/4885KDM4E 1704/4885IP6K1 404/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | L3MBTL1 220/4885KDM4E 4774/4885IP6K1 3034/4885 |
| US-20120208796-A1 | HETEROCYCLIC DERIVATIVES | CHRNA5, CHRM5, CHRNA7 | L3MBTL1 4613/4885KDM4E 2824/4885IP6K1 3231/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | L3MBTL1 220/4885KDM4E 4774/4885IP6K1 3034/4885 |
| US-20090149484-A1 | QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BRAF, RAF1, NRAS | L3MBTL1 4021/4885KDM4E 1746/4885IP6K1 1421/4885 |
| US-20250313551-A1 | PROCESS FOR THE PREPARATION OF A QUINAZOLINONE DERIVATIVE | NQO2, SDHA, NDUFS3 | L3MBTL1 4747/4885KDM4E 619/4885IP6K1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.